Sol-Gel Technologies (SLGL) vs Sutro Biopharma (STRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Sol-Gel Technologies (SLGL) has outperformed Sutro Biopharma (STRO) over the past year, gaining 75.5% versus a gain of 74.5%. Over five years, SLGL leads with a -22.8% price change compared with -92.3% for STRO. Sutro Biopharma is the larger company by market cap ($243.1 million vs $235.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SLGL | STRO |
|---|---|---|
| Share price | $71.95 | $14.66 |
| Market cap | $235.55M | $243.08M |
| 1-day change | -4.88% | +1.45% |
| YTD return | +70.73% | +26.71% |
| 1-year return | +75.52% | +74.52% |
| 5-year return | -22.85% | -92.28% |
| EPS (TTM) | $-5.34 | $-17.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $97.97 | $43.85 |
| 52-week low | $28.81 | $7.15 |
| Distance from 52-week high | -26.56% | -66.57% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +111.97% | +222.17% |
| Average volume | 55.68K | 289.73K |
| Shares outstanding | 3.27M | 16.58M |
| Employees | 28 | 128 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Sol-Gel Technologies
SLGL stock →Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Healthcare · Biotechnology · 28 employees
About Sutro Biopharma
STRO stock →Sutro Biopharma, Inc. operates as an oncology company.
Healthcare · Biotechnology · 128 employees
SLGL vs STRO FAQ
Which is bigger, Sol-Gel Technologies or Sutro Biopharma?
Sutro Biopharma (STRO) is larger, with a market capitalization of $243.08M compared with $235.55M for Sol-Gel Technologies (SLGL).
Which stock has performed better over the past year, SLGL or STRO?
SLGL returned +75.52% over the past 12 months, compared with +74.52% for STRO (price return, excluding dividends). Past performance does not predict future results.
Are Sol-Gel Technologies and Sutro Biopharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.